It was this association between MYCN amplification and the mTOR pathway along with the increasing use of the mTOR inhibitor temsirolimus (TEM) in clinical trials to treat NB that led to experiments combining TEM with MP1 reported in this manuscript. Here, MTOR is linked to neuroblastoma.